ROSEMONT

Liquid pharmaceuticals, namely, Antibacterial pharmaceuticals, Anti-diabetic pharmaceuticals, Cardiovascular pharmaceuticals, Lipid lowering agents, Psychotropics, and Anti-infectives; Liquid pharmaceutical preparations, namely, anticoagulants; Liquid pharmaceutical preparations, namely, antidepressants; Liquid pharmaceutical preparation for the treatment of gout; Liquid pharmaceutical preparations for the treatment of heart rhythm disorders; Liquid pharmaceutical preparations acting on the central nervous system; Liquid pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Liquid pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Liquid pharmaceutical preparations for treating diabetes; Liquid pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Liquid pharmaceutical preparations for the treatment of inflammatory disorders; Liquid pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Liquid pharmaceutical products for the treatment of bone diseases; Liquid pharmaceutical products for the treatment of viral and infectious diseases, and for the treatment of cancer